CJC-1295 No DAC (Modified GRF 1-29)

CJC-1295 No DAC (Modified GRF 1-29) Peptide

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 Format: Sterile Lyophilized Powder (Vial) Class: Tetrasubstituted GHRH Analogue Half-Life: ~30 Minutes (Pulsatile) Purity: >99% (HPLC) Content: Available in 5mg and 10mg vials

Product Overview

CJC-1295 No DAC, scientifically known as Modified GRF 1-29, is a rational engineering triumph in neuroendocrinology. It is a synthetic, tetrasubstituted analogue of the native Growth Hormone-Releasing Hormone (GHRH) 1-29 fragment.

Unlike native GHRH, which is degraded within minutes, Modified GRF 1-29 incorporates four specific amino acid substitutions that render it resistant to enzymatic cleavage (DPP-IV) and chemical oxidation. This extends its biological half-life to approximately 30 minutes. Crucially, because it lacks the Drug Affinity Complex (DAC), it preserves the natural, pulsatile secretion of Growth Hormone, avoiding the "GH bleed" and receptor desensitization associated with continuous long-acting analogs.

Mechanism of Action: The Pulsatile Signal

Modified GRF 1-29 acts as a selective agonist for the GHRH Receptor (GHRH-R) on pituitary somatotrophs.

• cAMP-PKA Pathway: Binding triggers the Gs-protein cascade, increasing intracellular cAMP. This initiates both immediate vesicle release (secretion) and long-term gene transcription (synthesis via Pit-1).

• DPP-IV Resistance: The substitution of D-Alanine at position 2 prevents the enzyme DPP-IV from cleaving the peptide, ensuring sustained receptor activation compared to native Sermorelin.

• Synergy: It effectively "loads the gun" (synthesis), making it highly synergistic with Ghrelin mimetics (GHRPs) that "pull the trigger" (release).

Chemical Engineering: The 4 Modifications

The "Modified" designation refers to four specific changes to the native sequence that optimize stability for research use:

1. Tyr1-D-Ala2: Confers resistance to DPP-IV digestion.

2. Gln8: Replaces Asparagine to prevent deamidation and improve shelf-stability.

3. Ala15: Replaces Glycine to stabilize the alpha-helical structure for better receptor binding.

4. Leu27: Replaces Methionine to prevent oxidation (sulfoxide formation) during storage.

Key Research Applications

1. Pulsatile GH Secretion Research confirms that Modified GRF 1-29 amplifies the natural peaks of GH secretion without elevating the basal "trough" levels. This mimics youthful physiology and allows for receptor resensitization between pulses.

2. Sleep Architecture (SWS) GHRH is a potent somnogenic factor. Studies utilizing EEG monitoring indicate that administration prior to the sleep window enhances Slow Wave Sleep (SWS) and Delta wave power, which correlates with improved cognitive recovery and endogenous hormonal repair.

3. Lipolysis (Fat Loss) Through the pulsatile elevation of GH, Modified GRF 1-29 activates Hormone Sensitive Lipase (HSL) in adipocytes. Research shows a preference for visceral adipose tissue reduction, mediated by the downregulation of PPAR-gamma.

Storage & Handling

• Physical State: Lyophilized (Freeze-Dried) White Powder.

• Storage (Lyophilized): Store at -20°C (Freezer). Stable for >24 months.

• Reconstitution:

  • Solvent: Bacteriostatic Water or Sterile Saline.

  • Solubility: Highly soluble (polar/basic profile).

• Storage (Reconstituted): Store at 4°C (Refrigerator). Use within 14-21 days. The Leu27 substitution significantly improves solution stability compared to native GHRH.

Disclaimer

FOR RESEARCH USE ONLY. This product is a chemical compound intended strictly for laboratory research and development. It is not approved by the FDA for clinical use, diagnostics, or therapeutic procedures in humans or animals. The physiological and toxicological properties of this chemical have not been fully investigated.